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OPEN
ORIGINAL ARTICLE
Association of a complement receptor 1 gene variant with
baseline erythrocyte sedimentation rate levels in patients starting
anti-TNF therapy in a UK rheumatoid arthritis cohort: results
from the Biologics in Rheumatoid Arthritis Genetics and
Genomics Study Syndicate cohort
J Bluett1,8, I Ibrahim1,8, D Plant2, KL Hyrich1, AW Morgan3,4, AG Wilson5, JD Isaacs6 for BRAGGSS7 and A Barton1,2
Eligibility for anti-tumour necrosis factor (TNF) therapy in most European countries is restricted to severe, active rheumatoid arthritis
(RA). The DAS28 score is a marker of disease severity and incorporates one of two inflammatory markers, erythrocyte sedimentation
rate (ESR) or C-reactive protein. We aimed to determine the relation between genetic variants known to affect ESR and levels of
ESR in patients with active RA. DNA samples were genotyped for four single-nucleotide polymorphisms (SNPs) rs7527798
(CR1L), rs6691117 (CR1), rs10903129 (TMEM57) and rs1043879 (C1orf63). The association between SNPs and baseline ESR, baseline
DAS28-ESR, and change in DAS28-ESR was evaluated. Baseline ESR was significantly associated with CR1 rs6691117 genotype
(P¼ 0.01). No correlation was identified between baseline DAS28-ESR or change in DAS28-ESR. In conclusion, genetic variation in
the gene encoding CR1 may alter ESR levels but not DAS28-ESR, indicating no adjustment for CR1 genotype is required in the
assessment of patients with severe active RA.
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INTRODUCTION
The development of biologic drugs that block the tumour necrosis
factor (TNF) pathway has revolutionized rheumatoid arthritis (RA)
treatment and patient prognosis. Anti-TNF drugs reduce joint
inflammation, diminish radiological damage and may reduce
cardiovascular risk.1,2 However, due to increased risk of infection,
inefficacy in a subset of patients and the economic impact,
predictors of treatment response would be a major clinical
advance.3 In the United Kingdom, eligibility for biologics is
determined by guidance issued by the National Institute for
Health and Clinical Excellence (NICE).4 Eligibility to commence and
maintain treatment with anti-TNF therapy is determined by the 28
joint-count disease activity score (DAS28).5 The DAS28 is an
assessment used to measure the level of disease activity in
patients with RA and has been validated in several studies.6–8
A score ofX5.1 on two separate occasions at least 1 month apart
is required before UK patients are eligible for anti-TNF therapy.
DAS28 is a composite index of RA disease activity, which
includes number of swollen and tender joints in 28 specified
joints, patient global health as measured by a visual analogue
scale and one of two inflammatory markers, erythrocyte
sedimentation rate (ESR) or C-reactive protein (CRP).6 CRP is an
acute-phase protein that is produced by the liver and is very
sensitive to short-term changes in inflammation.9 ESR is measured
by the rate at which red blood cells sediment over 1 h and is
reported in mmhÿ 1. In contrast to CRP, raised ESR indicates long-
standing, chronic inflammation and is an indirect measure of
acute-phase protein levels with a slower response after
inflammatory stimulation or resolution.9 ESR is increased in a
variety of conditions including pregnancy, myeloma, anaemia and
is further affected by age and gender, but this is not controlled for
in the calculation of the DAS28-ESR.10 A recent genome-wide
association study identified single-nucleotide polymorphisms
(SNPs) in several genes, which were associated with ESR levels
at genome-wide significance thresholds (Pp1 10ÿ 8) including
CR1 rs6691117.11 If this genetic correlation is also observed in RA
patients, it could have important clinical implications when
assessing eligibility for anti-TNF therapy using the DAS28-ESR.
CR1 encodes complement receptor 1 (CD35), a membrane
glycoprotein present on erythrocytes and leucocytes that acts as
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a negative regulator of the complement cascade by increasing
clearance of complement opsonized immune complexes, thus
preventing immune complex deposition.12–14
The aim of the current study was first, to investigate the
importance of known genetic variants that affect ESR and determine
whether they significantly influence ESR levels in UK patients with
active RA, and secondly, to determine whether the genetic variants
correlate with treatment response to anti-TNF medication. We aimed
to investigate the rs7527798, rs6691117, rs10903129 and rs1043879
SNPs mapping to the CR1L, CR1, TMEM57 and C1orf63 genes,
respectively, which have each been associated with ESR levels, to
determine their association with baseline ESR, baseline DAS28-ESR
and change in DAS28-ESR in patients with RA before and after
6 months therapy with an anti-TNF drug.
MATERIALS AND METHODS
Subjects
DNA samples from patients included in this study were obtained from the
Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate
(BRAGGSS). Patients eligible for the BRAGGSS cohort were initially
identified through the British Society for Rheumatology Biologics Register
(BSRBR). The BSRBR is a prospective observational study of patients with
rheumatic diseases newly commenced on anti-TNF biologic therapy, who
are followed up every 6 months for a period of at least 5 years.15 One of
the fundamental objectives of the BSRBR is to monitor patient progress, as
well as the incidence of long- and short-term side effects. The BRAGGSS
cohort was developed for the study of genetic predictors of response to
anti-TNF biologic therapy. Consultants at contributing centres across the
United Kingdom gave permission to identify their patients from the BSRBR;
eligible patients were approached by letter and invited to donate blood
samples for DNA extraction when they were due for a routine blood test.
Samples were posted to the Arthritis Research UK Epidemiology Unit for
processing, storage and analyses. All contributing patients provided
informed consent, and the study was approved by a multicenter ethics
committee (COREC 04/Q1403/37).
Baseline and 6-month DAS28 values were recorded to allow subsequent
analysis. Patients were excluded from this study if they had stopped
treatment because of adverse events or reasons other than inefficacy, or
after any change in their anti-TNF biologic therapy during the follow-up
period.
Genotyping
DNA samples were genotyped using the Sequenom MassArray iPLEX
system. In each reaction, 10 ng of DNA was used and the protocol was
followed according to the manufacturer’s instructions (http://www.
Sequenom.com). For each marker, negative water controls were included
for each experiment, and genotype cluster plots were manually reviewed.
In addition, SNPs were assessed for deviation from Hardy–Weinberg
equilibrium. For purposes of quality control, a 90% sample threshold and
90% genotyping success threshold were used.
Statistics
Baseline levels of ESR in the cohort studied did not follow a
normal distribution and were positively skewed; thus, baseline ESR
values were log-transformed before analysis. The association between
SNPs and ESR was evaluated with linear regression under an additive effect
model. Analyses were repeated adjusting for gender and age at baseline.
Linear regression models were also used to analyze DAS28-ESR and
change in DAS28-ESR over a 6-month period of treatment with anti-TNF
therapy.
These analyses were performed using STATA V.11.2 (http://www.stata.
com). Power calculations were performed using Quanto (version 1.2.3)
(http://hydra.usc.edu/gxe) under an additive model for a range of
marker-allele frequencies.
RESULTS
Clinical response and demographic data were recorded in 2978
patients. In total, 264 stopped their anti-TNF drug for reasons
other than inefficacy, 12 had no recorded information regarding a
potential change in their therapy and 146 had either an
incomplete baseline DAS28 or 6-month follow-up DAS28.
The rs7527798 (CR1L), rs6691117 (CR1), rs10903129 (TMEM57)
and rs1043879 (C1orf63) SNP markers were genotyped in 1510
DNA samples. The genotyping success rates for rs7527798,
rs6691117, rs1043879 and rs10903129 were 96%. Ninety-six
individuals were removed due to genotype success o90%.
In total, 1223 samples were successfully genotyped for all four
SNPs with recorded baseline DAS28 and 6-month follow-up DAS28.
Of the samples with genotype information, ESR serum measure-
ments were available for 1188 samples at baseline (pretreatment)
and 1195 samples at 6 months. Table 1 describes the demographic
and disease characteristics of the BRAGGSS cohort. Genotype fre-
quencies of all four markers conformed to Hardy–Weinberg
equilibrium (Table 2). For 1223 individuals for whom change in
DAS28-ESR was available, the study had 480% power (at the 5%
significance threshold) to detect a clinically meaningful difference
of 0.6 DAS28-ESR units for an allele frequency of 5%.
As expected, following treatment with anti-TNF therapy, we
noted a decrease in serum ESR levels and DAS28-ESR within the
BRAGGSS cohort. Age was significantly associated with higher
baseline ESR, baseline DAS28 and DAS28 6 months after anti-TNF
treatment (Po0.001,¼ 0.002 ando0.001, respectively). Female
sex was significantly associated with higher baseline ESR, baseline
DAS28 and DAS28 6 months after anti-TNF treatment (P¼ 0.004,
o0.001 ando0.001, respectively).
Two copies of rs6691117 CR1 GG minor allele were significantly
associated with baseline ESR, as shown in Table 2, but not ESR after
6 months of treatment or change of ESR. After correcting for gender
and age effects the statistical significance remained (P¼ 0.01).
Association remained after correcting for anti-CCP serology. The
CR1 rs6691117 GG was not significantly associated with baseline
DAS28-ESR, change in DAS28-ESR or DAS28-ESR after 6 months of
treatment (P¼ 0.99, 0.78, 0.77 respectively). The CR1L rs7527798 CC
genotype was significantly associated with change in DAS28-ESR
following 6 months treatment with anti-TNF therapy (P¼ 0.05) but
not change in ESR over the same period (P¼ 0.26). These data are
presented in Supplementary Tables S1–5.
DISCUSSION
Recent reports have identified that genetic variants on chromo-
some 1 affect ESR levels. This has potentially important
consequences for RA patients as eligibility for anti-TNF therapy
is determined by DAS28, which may incorporate ESR as a
Table 1. Demographic and disease characteristics
Agea (years) 56.75 (10.89)
Disease durationb (years) 12 (6–20)
Sex, F: n (%) 951 (77.76)
ESR at baselineb, mmhÿ 1 40 (25–66)
Change in ESRb, mmhÿ 1 ÿ 14 (ÿ 3–ÿ 30)
DAS28-ESR at baselinea 6.67 (0.97)
Change in DAS28-ESRa ÿ 2.49 (1.52)
Concurrent methotrexate therapy, n (%) 705 (57.65)
Rheumatoid factor positive, n (%) 719 (64.31)
Anti-CCP positive, n (%) 828 (80.78)
Infliximab, n (%) 490 (40.07)
Etanercept, n (%) 493 (40.31)
Adalimumab, n (%) 240 (19.62)
Abbreviations: DAS28, Disease Activity Score 28; ESR, erythrocyte
sedimentation rate; F, female; IQR, interquartile range.
aValues are expressed as mean (s.d.).
bValues are expressed as median (IQR). All other values are n (%). Disease
duration was measured in 1180 patients; baseline erythrocyte sedimenta-
tion was recorded in 1188 patients; change in ESR was recorded in 1195
patients; and change in DAS28-ESR was available in 1188 patients.
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biomarker of inflammation. Therefore, as genetic markers affect
ESR levels, these markers could influence treatment decisions and
could have adverse consequences for those patients who carry
the genotypes associated with lower ESR, as they would be less
likely to meet eligibility criteria for anti-TNF therapy.
In the current study, two copies of the AA major allele in
rs6691117 of the CR1 gene are significantly associated with lower
baseline ESR levels prior to anti-TNF therapy in keeping with the
direction of effect reported by Kullo et al.11 (P¼ 7 10ÿ 12).
Importantly, however, the genotype did not associate with
baseline DAS28-ESR. Although we were unable to adjust for all
factors that are associated with ESR, in particular haemoglobin
levels, we were able to adjust for age and gender that did not
qualitatively affect the results. While this is reassuring, the current
cohort had severe active RA, and therefore higher ESR compared
with the cohort in Kullo et al.11 (46.8 versus 13.1mmhÿ 1 in the
discovery cohort).16 We cannot exclude that the genetic markers
affecting ESR levels may still impact DAS28-ESR in patients with
less active inflammatory disease than this severe active RA cohort.
If the DAS28 thresholds were to be reduced in the future, the
genetic markers may influence the eligibility for anti-TNF therapy.
Collection of a cohort of patients with early RA would be required
to investigate this possibility. Our primary aim was to investigate if
genetic markers affected the eligibility to being started on any
anti-TNF; we are unable to investigate a class effect between anti-
TNF treatments as the reduced sample size would have limited
power. CR1 is a potent inhibitor of complement activation and
genetic variation within this gene may affect Rouleaux formation
and hence ESR. The rs6691117 is a non-synonymous SNP encod-
ing an isoleucine to valine alteration. This may modify the secon-
dary structure of CR1 affecting its ability to clear complement
opsonized immune complexes, thereby increasing ESR.
Carriage of the minor allele CC at rs7527798 (CR1L) was
associated with change in DAS28-ESR, but not baseline ESR or
change of ESR. This most likely represents a false-positive result as
the rs7527798 polymorphism has not, to our knowledge, been
associated with swollen joints, tender joints or patient global health.
Failure to detect an association with baseline or 6-month
DAS28-ESR may reflect inadequate power to detect modest
effects. However, despite not reaching significance thresholds, the
direction of effect for rs7527798, rs6691117, rs10903129 and
rs1043879 were in keeping with previously reported directions in
a previous association study.11
CRP can also be used to calculate DAS28-CRP. A previous study
has shown that genetic variants at the CRP locus correlate with the
level of CRP.17 However, a recent study has shown that for patients
with severe active RA, CRP and DAS28-CRP are not affected by
these genetic markers.18
CONCLUSIONS
In summary, rs6691117 polymorphism has been shown to
influence ESR levels in patients with very active inflammation
but not DAS28-ESR. This is reassuring for those patients starting
anti-TNF, but further studies with a cohort that includes a wide
range of DAS28-ESR levels would be required to ensure rs6691117
does not affect DAS28-ESR and hence eligibility for anti-TNF
therapy.
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